"Like other alpha-blockers, doxazosin has been associated with significant decreases in total and LDL serum cholesterol and serum triglycerides. This beneficial effect on the lipid profile may be important in some patients with ischemic heart disease.
Data from ALLHAT (which led to the discontinuation of the doxazosin-treatment arm of the study) indicated that users of doxazosin had 25% more cardiovascular events and were twice as likely to be hospitalized for congestive heart failure compared to users of chlorthalidone. However, these two drugs were found to be similarly effective in preventing heart attacks and in reducing the risk of death from all causes.[Ref]
Cardiovascular side effects are the most common. Dizziness has been reported in 3% to 14% of patients and is most likely to occur 2 to 6 hours after dosing. It may be minimized by administration of the drug at bedtime, particularly at the beginning of therapy. Rarely, syncope has been associated with doxazosin, and appears to be more likely in patients greater than 65 years old. Peripheral edema, palpitations, chest pain, and tachycardia have been reported in 7%, 4%, 3%, and 2% of patients, respectively.
Cerebrovascular accidents, postural dizziness, bradycardia, cardiac arrhythmias, and myocardial infarction have been reported in postmarketing studies.
Patients treated with doxazosin during the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) had a greater likelihood of developing congestive heart failure.[Ref]"
- Doxazosin Information for Consumers
- Doxazosin Information for Healthcare Professionals (includes dosage details)
- Side Effects of Doxazosin (detailed)
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Posted 23 Nov 2014 • 2 answers
Posted 24 Feb 2015 • 2 answers
Posted 7 Mar 2015 • 1 answer
Posted 30 Dec 2015 • 0 answers
Posted 1 Jan 2017 • 0 answers